Showing results (61-70 of 169) with videos related to
Sort By:
Pageof 17
The American Journal of Psychiatry|February 3, 2004
Do clozapine and risperidone affect social competence and problem solving?Alan S Bellack, Nina R Schooler, Stephen R Marder, et al.Schizophrenia Research|August 23, 2019
Evaluating visual neuroplasticity with EEG in schizophrenia outpatientsJonathan K Wynn, Brian J Roach, Amanda McCleery, et al.Schizophrenia Bulletin|April 23, 2010
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?Robert W Buchanan, Richard S E Keefe, Daniel Umbricht, et al.Journal of Clinical Psychopharmacology|March 2, 2005
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategyLawrence J Albers, Vural Ozdemir, Stephen R Marder, et al.The Journal of Clinical Psychiatry|November 6, 2002
The effects of novel antipsychotics on glucose and lipid levelsDonna A Wirshing, Jennifer A Boyd, Laura R Meng, et al.Schizophrenia Bulletin|June 19, 2010
The brief negative symptom scale: psychometric propertiesBrian Kirkpatrick, Gregory P Strauss, Linh Nguyen, et al.Psychiatry Research. Neuroimaging|July 15, 2022
N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS studyYvonne S Yang, Richard J Maddock, Huailin Zhang, et al.The American Journal of Psychiatry|March 3, 2005
Remission in schizophrenia: proposed criteria and rationale for consensusNancy C Andreasen, William T Carpenter, John M Kane, et al.Journal of Clinical Psychopharmacology|May 20, 2024
Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive DyskinesiaChristoph U Correll, Leslie Citrome, Carlos Singer, et al.Schizophrenia Bulletin|November 25, 2011
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?Richard S E Keefe, Robert W Buchanan, Stephen R Marder, et al.Pageof 17